Published : 15 Nov 2021
Aagami successfully delivered an IP Audit Analysis & Valuation report to their European Client. Aagami executes and delivers such projects through their IP Research partner (among Top 5 in the world).
The client is developing their Phase 2 candidate for, the treatment of Rheumatoid Arthritis and prevention of complications arising from COVID-19 infections such as acute respiratory distress failure.
The drug candidate is a first in class phase 2 oral drug in development for RA.
Aagami’s primary assignment was to support the European client in finding licensing/co-development partnerships in regions such as India and Korea. As several discussions opened up, the need for deal terms sparked a discussion, and an IP audit analysis and valuation was essential.
A separate assignment was undertaken and the report including valuation delivered to the client in a timely manner.